Navigation Links
BioTech Medical Well-Positioned to Immediately Respond to Swine Flu Emergency with SDC-Based SpectraSan 24 Disinfectant
Date:4/28/2009

SAN DIEGO, April 28 /PRNewswire/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its distributor, BioTech Medical, LLC, is well-positioned to immediately respond to the current swine flu emergency with its SDC-based SpectraSan 24(TM) disinfectant. SpectraSan 24, which meets the recommendations by the United States Centers for Disease Control (CDC) for infection control for care of patients with confirmed or suspected Swine Influenza A (H1N1) virus in both home and healthcare settings.

Andrea L. Goren, Executive Director of BioTech Medical, LLC, stated, "We are prepared and well-positioned to supply a much needed preventative solution to this potentially dangerous swine flu outbreak. BioTech Medical has a long-term history of successfully selling innovative healthcare products through various market channels and representative groups to multiple segments of the healthcare industry, including hospitals, long-term care facilities, clinics and doctors' offices throughout the United States as well as internationally."

Ms. Goren continued, "In addition to our existing marketing organization, we have the staff, warehousing facilities, distribution capability and capital resources to rapidly deliver SpectraSan 24 to all facets of not only healthcare but also institutions, businesses and the hospitality industry. We also have entree into schools, day care, athletic facilities and all modes of transportation such as airlines, cruise lines, rail and bus lines including all regional transit authorities. We also intend to offer SpectraSan 24 directly to consumers and through retail outlets in conjunction with our parent company, SCI Industries."

According to the CDC, person-to-person transmission of flu occurs mainly through coughing or sneezing of people infected with the influenza virus. People may become infected by touching something with the flu viruses on it and then touching their mouths or noses. Guidance published by the CDC on April 24, 2009 for infection control in healthcare settings advises that "disinfection strategies used during influenza seasons can be applied to the environmental management of swine influenza." Additional guidance published on April 25, 2009 for infection control in the home recommends keeping "surfaces (especially bedside tables, surfaces in the bathroom, and toys for children) clean by wiping them down with a household disinfectant according to directions on the product label."

PURE's SDC-based disinfectants have been registered by the EPA specifically for use on children's toys, cribs, high chairs and other sensitive areas of the home as well as for use on hard surfaces in multitudes of environments, including hospitals, schools and offices.

SpectraSan 24's broad spectrum power completely and rapidly eliminates bacteria, fungi and viruses, including Influenza A. SpectraSan 24 also carries a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria, a 10-minute kill time on fungi, a 30-second kill time on HIV Type I, and 10-minute kill times on other pathogenic viruses. These claims distinguish the efficacy of SpectraSan 24 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, SpectraSan 24 is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.

About BioTech Medical, LLC

BioTech Medical, LLC is a North Canton, Ohio based division of privately-held SCI Industries, a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical's multiple business segments are each focused on the distribution of innovative healthcare products, including the SDC-based SpectraSan 24 and Cruise Control hard surface disinfectants. For more information, please visit www.biotechmedicalllc.com.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE BioTech Medical, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Biotech Finishes on a High in August, Burrill Report Says
3. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
4. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
5. Biotech delists shares from TSXV, continues OTCBB trading
6. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
7. MichBio Announces Formation of Biotechnology Legislative Caucus
8. Oncolytics Biotech Inc. announces approval for UK clinical trial
9. Not just humans benefit from animal biotechnology
10. Biotech adds Central American markets to Sucanon distribution
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: